SMAD2 and fibrosis: Fibrosis, one of the major causes of morbidity and mortality in ALMS, is primarily driven by TGF-β ligands, especially activators of the SMAD2/3 axis, which is upregulated in many human fibrotic conditions (Walton et al., 2017).